Mutation of the palmitoylation site of estrogen receptor α in vivo reveals tissue-specific roles for membrane versus nuclear actions

Significance The in vivo roles of plasma membrane-associated estrogen receptor (ER)α, including cross-talk with nuclear ERα, are poorly understood. We created a mouse with a point mutation of the palmitoylation site of ERα (C451A-ERα) to obtain membrane-specific loss of function. A complementary mouse lacking the ERα activation function AF-2 (ERα-AF20) provided selective loss of function of nuclear ERα actions. Physiologic studies revealed critical requirements for membrane receptors in ovarian function and thereby in fertility, and in vascular physiology. In contrast, nuclear ERα actions mediate uterine responses to estrogen and genome-wide analysis indicates that membrane-to-nuclear receptor cross-talk in vivo is quite modest in uterus. These findings demonstrate for the first time critical tissue-specific roles for membrane versus nuclear actions of a steroid hormone receptor in vivo. Estrogen receptor alpha (ERα) activation functions AF-1 and AF-2 classically mediate gene transcription in response to estradiol (E2). A fraction of ERα is targeted to plasma membrane and elicits membrane-initiated steroid signaling (MISS), but the physiological roles of MISS in vivo are poorly understood. We therefore generated a mouse with a point mutation of the palmitoylation site of ERα (C451A-ERα) to obtain membrane-specific loss of function of ERα. The abrogation of membrane localization of ERα in vivo was confirmed in primary hepatocytes, and it resulted in female infertility with abnormal ovaries lacking corpora lutea and increase in luteinizing hormone levels. In contrast, E2 action in the uterus was preserved in C451A-ERα mice and endometrial epithelial proliferation was similar to wild type. However, E2 vascular actions such as rapid dilatation, acceleration of endothelial repair, and endothelial NO synthase phosphorylation were abrogated in C451A-ERα mice. A complementary mutant mouse lacking the transactivation function AF-2 of ERα (ERα-AF20) provided selective loss of function of nuclear ERα actions. In ERα-AF20, the acceleration of endothelial repair in response to estrogen–dendrimer conjugate, which is a membrane-selective ER ligand, was unaltered, demonstrating integrity of MISS actions. In genome-wide analysis of uterine gene expression, the vast majority of E2-dependent gene regulation was abrogated in ERα-AF20, whereas in C451A-ERα it was nearly fully preserved, indicating that membrane-to-nuclear receptor cross-talk in vivo is modest in the uterus. Thus, this work genetically segregated membrane versus nuclear actions of a steroid hormone receptor and demonstrated their in vivo tissue-specific roles.

[1]  E. Levin,et al.  Integration of the extranuclear and nuclear actions of estrogen. , 2005, Molecular endocrinology.

[2]  E. Levin,et al.  Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. , 2000, Molecular endocrinology.

[3]  K. Korach,et al.  Estrogen receptor α AF-2 mutation results in antagonist reversal and reveals tissue selective function of estrogen receptor modulators , 2011, Proceedings of the National Academy of Sciences.

[4]  Konrad F. Koehler,et al.  Development of subtype-selective oestrogen receptor-based therapeutics , 2011, Nature Reviews Drug Discovery.

[5]  B. Mouillac,et al.  Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. , 2003, Molecular endocrinology.

[6]  G. Leclercq,et al.  Palmitoylation regulates 17β-estradiol-induced estrogen receptor-α degradation and transcriptional activity. , 2012, Molecular endocrinology.

[7]  M. Schumacher,et al.  Validation of an analytical procedure to measure trace amounts of neurosteroids in brain tissue by gas chromatography-mass spectrometry. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[8]  P. Chambon,et al.  The transactivating function 1 of estrogen receptor α is dispensable for the vasculoprotective actions of 17β-estradiol , 2009, Proceedings of the National Academy of Sciences.

[9]  H. Witkowska,et al.  Carboxymethylation of the human estrogen receptor ligand-binding domain-estradiol complex: HPLC/ESMS peptide mapping shows that cysteine 447 does not react with iodoacetic acid , 1996, Steroids.

[10]  C. Rosenfeld,et al.  Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. , 1997, The American journal of physiology.

[11]  E. Levin,et al.  Developmental Phenotype of a Membrane Only Estrogen Receptor α (MOER) Mouse* , 2009, Journal of Biological Chemistry.

[12]  A. Quyyumi,et al.  Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. , 1994, Circulation.

[13]  G. Kassab,et al.  Estrogen Induces Vascular Wall Dilation , 2005, Journal of Biological Chemistry.

[14]  R. Pietras,et al.  Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells , 1977, Nature.

[15]  C. Mineo,et al.  Non-nuclear Estrogen Receptor Signaling in the Endothelium* , 2011, The Journal of Biological Chemistry.

[16]  Cory C. Funk,et al.  Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. , 2006, Molecular endocrinology.

[17]  J. Greaves,et al.  The intracellular dynamic of protein palmitoylation , 2010, The Journal of cell biology.

[18]  I. Treilleux,et al.  Activation of rapid oestrogen signalling in aggressive human breast cancers , 2012, EMBO molecular medicine.

[19]  F. Lenfant,et al.  Key Role of Estrogens and Endothelial Estrogen Receptor &agr; in Blood Flow–Mediated Remodeling of Resistance Arteries , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[20]  S. Hammes,et al.  Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. , 2007, Annual review of physiology.

[21]  K. Ley,et al.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase , 2000, Nature.

[22]  F. Ebling,et al.  Methods for quantifying follicular numbers within the mouse ovary. , 2004, Reproduction.

[23]  J. Katzenellenbogen,et al.  Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release. , 2001, Molecular endocrinology.

[24]  P. Chambon,et al.  Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. , 2000, Development.

[25]  P. Visca,et al.  Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. , 2005, Molecular biology of the cell.

[26]  B. Katzenellenbogen,et al.  Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. , 2010, The Journal of clinical investigation.

[27]  R. Karas,et al.  Emerging evidence of the importance of rapid, non-nuclear estrogen receptor signaling in the cardiovascular system , 2013, Steroids.

[28]  F. Stossi,et al.  Genomic Collaboration of Estrogen Receptor α and Extracellular Signal-Regulated Kinase 2 in Regulating Gene and Proliferation Programs , 2010, Molecular and Cellular Biology.

[29]  G. Garcı́a-Cardeña,et al.  17 beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. , 1997, Circulation research.

[30]  T. Simoncini Mechanisms of action of estrogen receptors in vascular cells: relevance for menopause and aging , 2009, Climacteric : the journal of the International Menopause Society.

[31]  J. Bender,et al.  Membrane-initiated actions of estrogen on the endothelium , 2009, Molecular and Cellular Endocrinology.

[32]  R. Sainson,et al.  A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane* , 2007, Journal of Biological Chemistry.

[33]  R. Campbell,et al.  Estradiol negative and positive feedback in a prenatal androgen-induced mouse model of polycystic ovarian syndrome. , 2013, Endocrinology.

[34]  P. Chambon,et al.  Activation function 2 (AF2) of estrogen receptor-α is required for the atheroprotective action of estradiol but not to accelerate endothelial healing , 2011, Proceedings of the National Academy of Sciences.

[35]  K. Korach,et al.  Lessons in estrogen biology from knockout and transgenic animals. , 2005, Annual review of physiology.

[36]  D. Friend,et al.  HIGH-YIELD PREPARATION OF ISOLATED RAT LIVER PARENCHYMAL CELLS , 1969, The Journal of cell biology.

[37]  J. Davis,et al.  Adenosine 3',5'-monophosphate in rat uterus: acute elevation by estrogen. , 1967, Proceedings of the National Academy of Sciences of the United States of America.

[38]  E. Levin,et al.  Minireview: Recent Advances in Extranuclear Steroid Receptor Actions , 2011, Endocrinology.

[39]  Qing Lu,et al.  Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Kassab,et al.  Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. , 2005, The Journal of biological chemistry.

[41]  F. Lenfant,et al.  The AF-1 activation function of estrogen receptor α is necessary and sufficient for uterine epithelial cell proliferation in vivo. , 2013, Endocrinology.

[42]  C. Mineo,et al.  Coupling of Fc&ggr; Receptor I to Fc&ggr; Receptor IIB by Src Kinase Mediates C-Reactive Protein Impairment of Endothelial Function , 2011, Circulation research.

[43]  P. Chambon,et al.  The transactivating function-1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17 beta-estradiol. , 2009 .

[44]  B. Komm,et al.  Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. , 2008, Molecular endocrinology.

[45]  B. O’Malley,et al.  Nuclear receptor coregulators: modulators of pathology and therapeutic targets , 2012, Nature Reviews Endocrinology.

[46]  L. Björnström,et al.  Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. , 2002, Molecular endocrinology.

[47]  Rakesh Kumar,et al.  Signaling regulation of genomic and nongenomic functions of estrogen receptors. , 2006, Cancer letters.

[48]  Richard G. W. Anderson,et al.  Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. , 2000, Circulation research.